logo image
search icon
Non-Viral Transfection Reagents Market

Non-Viral Transfection Reagents Market Size, Share & Trends Analysis Distribution by Type of Non-Viral Transfection System (Non-Viral Transfection Reagents (chemical & physical), Electroporation-based Transfection Systems), Area of Application (Clinical Applications, Research Applications), End-User (Academic and Research Institutions, Pharmaceutical Companies) and Segment Forecasts, 2023-2031

Report ID : 2533 | Published : 2024-06-19 | Pages: 180 | Format: PDF/EXCEL

Non-Viral Transfection Reagents Market Size is valued at USD 649.1 Mn in 2023 and is predicted to reach USD 1,157.5 Mn by the year 2031 at an 7.7% CAGR during the forecast period for 2024-2031.

Non-Viral Transfection Reagents Market info

Non-viral transfection reagents represent a significant advancement in genetic manipulation techniques, offering researchers a diverse toolkit for delivering genetic material into cells. Among the several types of non-viral reagents, lipid-based formulations stand out for their ability to efficiently encapsulate nucleic acids within lipid nanoparticles. This encapsulation shields the genetic material from degradation and facilitates its uptake by cells, leading to higher transfection efficiencies. Additionally, lipid-based reagents are known for their biocompatibility and low immunogenicity, minimizing the risk of adverse reactions, and making them suitable for a wide spectrum of applications in both research and therapeutic settings.

Another notable category of non-viral transfection reagents is polymer-based formulations, such as polyethyleneimine (PEI) and polylysine. These polymers can form complexes with nucleic acids through electrostatic interactions, enabling efficient delivery into target cells. Polymer-based reagents offer advantages such as tunable properties, allowing researchers to optimize transfection conditions for specific cell types or experimental requirements.

A key driver for the expansion of the non-viral transfection reagents market is the growing interest in nucleic acid-based therapies. These therapies are pivotal in treating various diseases and hinge on the adept delivery of genetic material into cells. Their efficacy in this realm underscores their indispensable role in advancing advancements in gene therapy and gene editing applications. This escalating demand underscores the pivotal role non-viral transfection reagents play in catalyzing the evolution of these transformative treatments.

Competitive Landscape

Some of the Key Players in Non-Viral Transfection Reagents Market:

  • Altogen Biosystems
  • Altogen Biosystems
  • BEX
  • Bio-Rad Laboratories
  • BTX
  • Celsion
  • Genlantis (now part of Rockland Immunochemicals
  • Genprex
  • Imunon (Formerly known as Celsion)
  • Inovio Pharmaceuticals
  • Lonza Group,
  • MaxCyte
  • MilliporeSigma
  • Mirus Bio LLC
  • Nepa Gene
  • OZ Biosciences
  • Polyplus-Transfection SA.
  • Promega Corporation
  • Qiagen
  • Sigma-Aldrich (now part of Merck)
  • Takara Bio
  • Thermo Fisher Scientific (TFS)
  • Other Prominent Players

Market Segmentation:

The non-viral transfection reagents market is segmented based on the type of non-viral transfection system, area of application and end user. By type of non-viral transfection system market is segmented into non-viral transfection reagents (chemical and physical), electroporation-based transfection systems, and other non-viral transfection systems. By area of application, the market is segmented into clinical and research applications. End user market is categorized into academic and research institutions, pharmaceutical companies, and other end-users.

Clinical Applications is Expected to Drive the Non-Viral Transfection Reagents Market in the Upcoming Years.

The Clinical Applications segment is the driving force behind the growth of the Non-Viral Transfection Reagents Market. This surge is propelled by the escalating demand for gene therapy and the urgent need for safer, more controlled methods of gene delivery in clinical settings. Gene therapy is increasingly favored as a treatment modality for genetic disorders, cancer, and numerous other diseases. Within this realm, non-viral transfection reagents play a pivotal role, facilitating the successful delivery of therapeutic genes into target cells. This segment prioritizes the critical safety, efficacy, and precision requirements demanded by clinical applications. Compared to viral vectors, non-viral transfection reagents offer distinct advantages, including enhanced safety profiles devoid of viral vector-associated immune responses or insertional mutagenesis risks, making them indispensable for clinical use.

The Pharmaceutical Companies Segment is Growing at the Highest Rate in the Non-Viral Transfection Reagents Market.

Due to several key factors, the Pharmaceutical Companies segment is witnessing significant growth within the Non-Viral Transfection Reagents Market. These companies increasingly turn to non-viral transfection reagents for drug discovery and development, primarily driven by their regulatory benefits, cost-efficiency, scalability, and experimental design flexibility. Non-viral transfection reagents offer regulatory advantages, making them indispensable tools in pharmaceutical research and development. Additionally, their cost-effectiveness compared to viral vectors and ease of scalability for large-scale production further attract pharmaceutical companies. Moreover, the flexibility in experimental design afforded by non-viral transfection reagents allows these companies to tailor their research and development processes to meet specific requirements, thereby driving their adoption and contributing to the segment's significant growth within the market.

Regionally, Asia Pacific Led the Non-Viral Transfection Reagents Market.

The Asia Pacific region is experiencing a surge in the demand for non-viral transfection reagents, led by the rapid expansion of its biotechnology and pharmaceutical industries. With numerous companies actively developing and commercialising these reagents, the region's industry growth is palpable. Moreover, the burgeoning demand for gene therapy and RNA-based therapeutics further fuels this expansion, as these therapies heavily rely on efficient and safe delivery systems provided by non-viral transfection reagents. Additionally, Asia Pacific stands at the forefront of gene editing and gene therapy research.

Recent Developments:

  • In May 2024, MilliporeSigma, the U.S. and Canada Life Science division of Merck KGaA, Darmstadt, Germany, has finalized a deal to acquire Mirus Bio for $600 million. Mirus Bio, a subsidiary of Gamma Biosciences specializes in the research and distribution of transfection reagents, including TransIT-VirusGEN. These reagents are instrumental in the manufacturing process of gene therapies based on viral vectors. This acquisition underscores MilliporeSigma's commitment to advancing innovation in the life sciences sector, particularly in the critical field of gene therapy production.

Non-Viral Transfection Reagents Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 649.1 Mn

Revenue Forecast In 2031

USD 1,157.5 Mn

Growth Rate CAGR

CAGR of 7.7% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Mn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type of Non-Viral Transfection System, Area of Application, End User

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape

Altogen Biosystems, Bio-Rad Laboratories, BEX, BTX, Celsion, Genprex, Inovio Pharmaceuticals, MaxCyte, MilliporeSigma, Nepa Gene, OZ Biosciences, Thermo Fisher Scientific, Other Prominent Players

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Non-Viral Transfection Reagents Market Snapshot

Chapter 4. Global Non-Viral Transfection Reagents Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Type of Non-Viral Transfection System Estimates & Trend Analysis

5.1. by Type of Non-Viral Transfection System & Market Share, 2019 & 2031

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type of Non-Viral Transfection System:

5.2.1. Non-Viral Transfection Reagents

5.2.1.1. Chemical-based Transfection

5.2.1.2. Physical Transfection Systems

5.2.2. Electroporation-based Transfection Systems

5.2.3. Other Non-Viral Transfection Systems

Chapter 6. Market Segmentation 2: by Area of Application Estimates & Trend Analysis

6.1. by Area of End-User & Market Share, 2019 & 2031

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Area of End-User:

6.2.1. Clinical End-Users

6.2.2. Research End-Users

Chapter 7. Market Segmentation 3: by End-User Estimates & Trend Analysis

7.1. by End-User & Market Share, 2019 & 2031

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-User:

7.2.1. Academic and Research Institutions

7.2.2. Pharmaceutical Companies

7.2.3. Other End-Users

Chapter 8. Non-Viral Transfection Reagents Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Type of Non-Viral Transfection System, 2023-2031

8.1.2. North America Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Area of Application, 2023-2031

8.1.3. North America Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

8.1.4. North America Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.2. Europe

8.2.1. Europe Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Type of Non-Viral Transfection System, 2023-2031

8.2.2. Europe Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Area of Application, 2023-2031

8.2.3. Europe Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

8.2.4. Europe Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Type of Non-Viral Transfection System, 2023-2031

8.3.2. Asia Pacific Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Area of Application, 2023-2031

8.3.3. Asia-Pacific Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

8.3.4. Asia Pacific Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.4. Latin America

8.4.1. Latin America Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Type of Non-Viral Transfection System, 2023-2031

8.4.2. Latin America Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Area of Application, 2023-2031

8.4.3. Latin America Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

8.4.4. Latin America Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Type of Non-Viral Transfection System, 2023-2031

8.5.2. Middle East & Africa Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by Area of Application, 2023-2031

8.5.3. Middle East & Africa Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

8.5.4. Middle East & Africa Non-Viral Transfection Reagents Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Altogen Biosystems

9.2.2. Bio-Rad Laboratories

9.2.3. BEX

9.2.4. BTX

9.2.5. Celsion

9.2.6. Genprex

9.2.7. Inovio Pharmaceuticals

9.2.8. MaxCyte

9.2.9. MilliporeSigma

9.2.10. Nepa Gene

9.2.11. OZ Biosciences

9.2.12. Thermo Fisher Scientific

9.2.13. Other Prominent Players

Segmentation Non-Viral Transfection Reagents Market –

Non-Viral Transfection Reagents Market by Type of Non-Viral Transfection System-

  • Non-Viral Transfection Reagents
    • Chemical-based Transfection
    • Physical Transfection Systems
  • Electroporation-based Transfection Systems
  • Other Non-Viral Transfection Systems

Non-Viral Transfection Reagents Market seg

Non-Viral Transfection Reagents Market by Area of Application -

  • Clinical Applications
  • Research Applications

Non-Viral Transfection Reagents Market by End User-

  • Academic and Research Institutions
  • Pharmaceutical Companies
  • Other End-Users

Non-Viral Transfection Reagents Market by Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Non-Viral Transfection Reagents Market Size?

Non-Viral Transfection Reagents Market is predicted to develop at an 7.7% CAGR during the forecast period for 2024-2031.

Inovio Pharmaceuticals, MaxCyte, MilliporeSigma, Nepa Gene, OZ Biosciences, Thermo Fisher Scientific, Other Prominent Players

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach